drugset
drugset / Trial / NCT04814485

Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer

NCT04814485 ↗

Phase 2 Unknown 39 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study is being conducted to explore the efficacy and safety of SHR-1020 combined with albumin-bound paclitaxel in the second-line treatment of advanced pancreatic cancer.

Timeline

Start
2021-04-22
Primary completion
2023-07
Completion
2023-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Famitinib Small molecule — —
Subject Paclitaxel Small molecule — —

Indications

malignant pancreatic neoplasm